Abstract
A clear relationship between vitamin D status and the clinical indices of primary hyperparathyroidism (pHPT) severity has not been convincingly established. We proposed that such a relationship might exist, in so far as vitamin D deficiency could contribute to the severity of metabolic bone disease and promote the growth of the parathyroid tumor. Accordingly, we undertook a retrospective study and analyzed the clinical, biochemical, radiological and histopathological findings in a group of 49 patients who underwent parathyroidectomy at our center. Patients who had skeletal X-rays were grouped, according to their X-ray findings, in group A (19 patients; 45%) if they had severe bone changes, or group B (23 patients; 55%) if they had mild or no bone changes. Patients were also stratified according to their 25-hydroxyvitamin D (25-OHD) levels in tertiles. The 2 groups were compared using Fisher’s exact test or analysis of variance as appropriate. Group A patients were younger (p=0.001), had more musculoskeletal symptoms (p=0.0003), and complained more frequently of fatigue (p=0.02). They had higher alkaline phosphatase (AP; p=0.0002), PTH index (p=0.0007), and serum Ca level (p=0.006). There were more patients from the lower and middle vitamin D tertiles and fewer patients from the upper vitamin D tertile in group A (p=0.02). Post-operative severe hypo-calcemia was more prevalent in group A patients (p<0.0001). Resected parathyroid tumors were larger in size in group A patients (p=0.01), and weighed more (p=0.01). There was a positive correlation between the weight of the parathyroid tumor and the PTH index (p=0.002), and AP level (p=0.0007). We concluded that vitamin D deficiency is a contributing factor to both the severity of bone disease and the high activity of parathyroid tumors seen in many patients with pHPT in vitamin D deficient regions.
Similar content being viewed by others
References
Silverberg SJ, Fitzpatrick LA, Bilezikian JP. Primary hyperthyroidism. In: Becker KL ed. Principles and Practice of Endocrinology and Metabolism. 2nd ed. Philadelphia: J.B. Lippincott Company. 1995, 512–20.
Harinarayan CV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol (Oxf) 1995, 43: 351–8.
Woodhouse NJY, Norton WL. Low vitamin D levels in Saudi Arabians. King Faisal Specialist Hospital Medical Journal 1982, 2: 127–31.
Fouda MA. Primary hyperparathyroidism: King Khalid University Hospital Experience. Ann Saudi Med 1999, 19: 110–5.
Ingemansson SG, Hugosson CH, Woodhouse NJY. Vitamin D deficiency and hyperparathyroidism with severe bone disease. World J Surg 1988, 12: 517–21.
Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000, 85: 1054–8.
Wortsman J, Haddad JG, Posillico JT, Brown EM. Primary hyperparathyroidism with low serum 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab 1986, 62: 1305–8.
Khosla S, Ebeling PR, Fireck AF, Burritt MM, Kao PC, Heath H 3rd. Calcium infusion suggests a “set-point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993, 76: 715–20.
Malberti F, Farina M, Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999, 14: 2398–406.
Fuleihan GEH. Pathogenesis and etiology of primary hyperparathyroidism. UpToDate, Inc. 1997.
Silver J, Yalcindag C, Sela-Brown A, Kilav R, Naveh-Many T. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int 1999, 56 (Suppl. 73): 2–7.
Cetani F, Pinchera A, Pardi E, et al. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res 1999, 14: 878–82.
Carling T, Ridefelt P, Hellman P, Rastad J, Akerstrom G. Vitamin D receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism. J Clin Endocrinol Metab 1997, 82: 1772–5.
Correa P, Rastad J, Schwarz P, et al. The vitamin D receptor (VDR) start codon polymorphism in primary hyperparathyroidism and parathyroid VDR messenger ribonucleic acid levels. J Clin Endocrinol Metab 1999 84: 1690–4.
Sudhaker Rao DS, Han Z-H, Phillips ER, Palnitkar S, Parfitt AM. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin Endocrinol (Oxf) 2000, 53: 373–81.
Carling T, Rastad J, Szabo E, Westin G, Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85: 2000–3.
Lumb GA, Stanbury SW. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974, 56: 833–9.
Kleeman CR, Norris K, Coburn JW. Is the clinical expression of primary hyperparathyroidism a function of the long-term vitamin D status of the patient? Mineral Electrolyte Metab 1987,13: 305–10.
Vaishnava H, Rizvi SNA. Primary hyperparathyroidism associated with nutritional osteomalacia. Am J Med 1969, 46: 640–4.
Sultan AH, Bruckner FE, Eastwood JB. Association between prolonged dietary vitamin D deficiency and autonomous hyperparathyroidism. Bmj 1989, 299: 236–7.
Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999, 107: 561–7.
Paillard M, Gardin J-P, Borensztein P, Prigent A. Determinants of parathormone secretion in primary hyperparathyroidism. Horm Res 1989, 32: 89–92.
Coen G, Bondatti F, de Matteis A, et al. Severe vitamin D deficiency in a case of primary hyperparathyroidism caused by parathyroid lipoadenoma, effect of 25OHD3 treatment. Miner Electrolyte Metab 1989, 15: 332–7.
Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities: New York and Beijing. Int J Fertil Womens Med 2000, 45: 158–65.
Miedlich S, Krohn K, and Paschke R. Update on genetic and clinical aspects of primary hyperparathyroidism. Clinical Endocrinol (Oxf) 2003, 59: 539–54.
Author information
Authors and Affiliations
Corresponding author
Additional information
Part of this work was presented as an abstract in the Endocrine Society meeting, 2000, in Toronto, Canada.
Rights and permissions
About this article
Cite this article
Raef, H., Ingemansson, S., Sobhi, S. et al. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest 27, 807–812 (2004). https://doi.org/10.1007/BF03346273
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346273